Viatris Inc (VTRS) stock
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/308% below fair value
$20.45−0.29 (-1.40%)
Close on Nov 17, 2026Market cap $23.49BP/E –Yield 2.35%
Viatris r&d expenses
Research and development expenses are spending on new products and technology.
Viatris's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.02B, up 20.8% year over year. For fiscal 2025 it was $965.90M, up 19.4% from the year before. The highest annual figure on record is $965.90M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $965.90M | +19.4% |
| FY2024 | Dec 31, 2024 | $808.70M | +0.4% |
| FY2023 | Dec 31, 2023 | $805.20M | +21.6% |
| FY2022 | Dec 31, 2022 | $662.20M | -2.8% |
| FY2021 | Dec 31, 2021 | $681.00M | +32.9% |
| FY2020 | Dec 31, 2020 | $512.60M | -19.9% |
| FY2019 | Dec 31, 2019 | $639.90M | -9.2% |
| FY2018 | Dec 31, 2018 | $704.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $248.30M | +13.5% |
| Q1 FY2026 | Mar 31, 2026 | $248.60M | +12.0% |
| Q4 FY2025 | Dec 31, 2025 | $274.70M | +33.0% |
| Q3 FY2025 | Sep 30, 2025 | $250.40M | +26.2% |
| Q2 FY2025 | Jun 30, 2025 | $218.80M | +7.2% |
| Q1 FY2025 | Mar 31, 2025 | $222.00M | +11.2% |
| Q4 FY2024 | Dec 31, 2024 | $206.50M | +1.8% |
| Q3 FY2024 | Sep 30, 2024 | $198.40M | -6.1% |
| Q2 FY2024 | Jun 30, 2024 | $204.10M | -2.0% |
| Q1 FY2024 | Mar 31, 2024 | $199.70M | +9.2% |
| Q4 FY2023 | Dec 31, 2023 | $202.80M | +11.2% |
| Q3 FY2023 | Sep 30, 2023 | $211.20M | +20.8% |
| Q2 FY2023 | Jun 30, 2023 | $208.30M | +28.1% |
| Q1 FY2023 | Mar 31, 2023 | $182.90M | +28.5% |
| Q4 FY2022 | Dec 31, 2022 | $182.40M | -7.5% |
| Q3 FY2022 | Sep 30, 2022 | $174.90M | +15.0% |
| Q2 FY2022 | Jun 30, 2022 | $162.60M | +10.1% |
| Q1 FY2022 | Mar 31, 2022 | $142.30M | -22.7% |
| Q4 FY2021 | Dec 31, 2021 | $197.10M | +75.5% |
| Q3 FY2021 | Sep 30, 2021 | $152.10M | +17.2% |
| Q2 FY2021 | Jun 30, 2021 | $147.70M | -5.5% |
| Q1 FY2021 | Mar 31, 2021 | $184.10M | +61.2% |
| Q4 FY2020 | Dec 31, 2020 | $112.30M | – |
| Q3 FY2020 | Sep 30, 2020 | $129.80M | – |
| Q2 FY2020 | Jun 30, 2020 | $156.30M | – |
| Q1 FY2020 | Mar 31, 2020 | $114.20M | – |
See a number that looks wrong?